Gynesonics Announces First Patient Successfully Treated With Newly Designed Incisionless VizAblate® System For Symptomatic Uterine Fibroids

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gynesonics, Inc., a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced the first treatment of a patient in Cologne, Germany, using the Company’s newly-designed VizAblate® System. VizAblate is the only medical device to integrate ultrasound imaging with radiofrequency ablation in a single handheld device for the treatment of fibroids. The System is minimally invasive and is inserted through the cervix without any need for incisions.

Help employers find you! Check out all the jobs and post your resume.

Back to news